

## A New Route to 4-*epi*-L-Daunosamine containing Disaccharides

Belgacem Abbaci,<sup>a</sup> Jean-Claude Florent,<sup>a</sup> and Claude Monneret<sup>\*b</sup>

<sup>a</sup> Département de Pharmacognosie associé au CNRS n° 484, Faculté des Sciences Pharmaceutiques et Biologiques, 4 avenue de l'Observatoire, 75270 Paris Cedex 06, France

<sup>b</sup> Service de Chimie, Institut Curie, Section de Biologie, 26 rue d'Ulm, 75231 Paris Cedex 05, France



The methyl 4-*O*-(2,6-dideoxy-2-iodo- $\alpha$ -L-mannopyranosyl)- $\alpha$ -L-acosaminide (**11**) and the methyl 4-*O*-(2,6-dideoxy- $\alpha$ -L-arabinopyranosyl)- $\alpha$ -L-acosaminide analogue (**12**) have been stereoselectively synthesized in seven and eight steps, respectively, from di-*O*-acetyl-L-rhamnol (**4**) and methyl 2,3,6-trideoxy- $\alpha$ -L-*erythro*-hex-2-enopyranoside (**5**); the key step involved a 1,4-addition of hydrazoic acid to a corresponding hex-2-enopyranose.

Polyoxygenated di- or tri-saccharides which contain 3-dimethylamino-2,3,6-trideoxy-L-*lyxo*-hexose (or L-rhodamine) as a reductive unit occur naturally in several anthracycline antibiotics such as musettamycin (**1**),<sup>1</sup> marcellomycin (**2**),<sup>2</sup> and aclacinomycin (**3**).<sup>2</sup> The total synthesis of these oligosaccharides has been achieved recently in our laboratory<sup>3</sup> as well as the synthesis of 4'-*epi*-L-rhodamine containing disaccharide.<sup>4</sup>

On the other hand, two years ago, we reported<sup>5</sup> that 3-amino-2,3,6-trideoxy- $\alpha$ -L-*arabino*-hexopyranoside (or methyl- $\alpha$ -L-acosaminide) can be synthesized stereoselectively after transformation of di-*O*-acetyl-L-rhamnol into the corresponding pseudo-glucal followed by a 1,4-addition of HN<sub>3</sub> to this  $\alpha,\beta$ -unsaturated aldehyde equivalent, as the key step.

Advantage of this strategy was taken for the synthesis of analogues of the oligosaccharide moieties present in anthracyclines (**1**)–(**3**). This method avoids the need for the synthesis of the fully functionalized and totally protected unit A, prior to the elaboration of the interglycosidic bond.

As depicted in Scheme 1, condensation of 3,4-di-*O*-acetyl- $\alpha$ -L-*arabino*-hex-1-enitol (or di-*O*-acetyl-L-rhamnol) (**4**)<sup>6</sup> with methyl 2,3,6-trideoxy- $\alpha$ -L-*erythro*-hex-2-enopyranoside (**5**) in the presence of *N*-iodosuccinimide<sup>7</sup> afforded, after flash chromatography (hexane–EtOAc, 4:1), the 2'-iodo-disaccharide (**6**) {syrup,  $[\alpha]_{D}^{20} = -126^{\circ}$  (*c* 1, CHCl<sub>3</sub>)} in 64% yield. Acid hydrolysis of (**6**) under mild conditions (AcOH–H<sub>2</sub>O, 4:3, 72 h, room temp.) was followed by addition of HN<sub>3</sub> to the crude mixture and stirring for 36 h at room temperature. After



**Scheme 1.** Reagents and conditions: i, *N*-iodosuccinimide, MeCN; ii, AcOH–H<sub>2</sub>O; iii, NaN<sub>3</sub>; iv, Ac<sub>2</sub>O; v, H<sub>2</sub>, Pd–C (10%), Et<sub>3</sub>N; vi, (CF<sub>3</sub>CO)<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>; vii, Ph<sub>3</sub>P–H<sub>2</sub>O; viii, TMSOTf, MeOH, –78 °C; ix, Bu<sub>3</sub>SnH, AIBN, benzene.

conventional acetylation, disaccharides (7)<sup>†</sup> {m.p. 112°C (CH<sub>2</sub>Cl<sub>2</sub>); [α]<sub>D</sub><sup>20</sup> -94° (c 1, CHCl<sub>3</sub>)} and (8) {m.p. 58°C (CH<sub>2</sub>Cl<sub>2</sub>); [α]<sub>D</sub><sup>20</sup> -30° (c 1, CHCl<sub>3</sub>)} were separated by column chromatography in 42 and 21% overall yields from (6), respectively.

Catalytic hydrogenation of (7) (Pd-charcoal 10%, Et<sub>3</sub>N, EtOAc, 15 min) followed by *N*-trifluoroacetylation gave the disaccharide (9) {55%, syrup; [α]<sub>D</sub><sup>20</sup> -12° (c 1, CHCl<sub>3</sub>)} whereas the corresponding 2'-iodo-disaccharide (10) {m.p. 215–216° (hexane-acetone); [α]<sub>D</sub><sup>20</sup> -84° (c1, CHCl<sub>3</sub>)} was obtained in 50% overall yield by reduction of the azide function of (9) under modified Staudinger conditions<sup>8</sup> (Ph<sub>3</sub>P-H<sub>2</sub>O-THF) (THF = tetrahydrofuran) followed by *N*-trifluoroacetylation of the amino-derivative. Moreover, glycosidation of (10) with methanol in the presence of trimethylsilyltri-fluoromethanesulphonate (TMSOTf) afforded stereospecifically the methyl-α-L-glycoside (11) {syrup; [α]<sub>D</sub><sup>20</sup> -54° (c 1, CHCl<sub>3</sub>)} in 75% yield.

<sup>†</sup> Selected <sup>1</sup>H NMR data (CDCl<sub>3</sub>) for (7): δ 6.09 (dd, 1-H), 5.41 (d, 1'-H), 5.08 (t, 4'-H), 4.62 (dd, 2'-H), 4.51 (dd, 3'-H), 4.05–3.70 (m, 3-H, 5-H, 5'-H), 3.12 (dd, 4-H), 2.22 (dd, 2e-H), 1.86 (m, 2a-H), 2.13, 2.10, 2.05 (3s, 3 OAc), 1.30, 1.25 (2d, 2 Me); for (8): δ 6.00 (dd, 1-H), 5.30 (d, 1'-H), 5.14 (t, 4'-H), 4.62 (dd, 2'-H), 4.54 (dd, 3'-H), 4.20 (m, 3-H), 4.12 and 4.00 (2 qd, 5-H and 5'-H), 3.62 (dd, 4-H), 2.09, 2.06 (2s, 3 OAc), 1.87 (m, 2a-H), 1.34, 1.23 (2d, 2 Me); for (11): δ 6.61 (d, NH), 5.25 (d, 1'-H), 5.18 (d, 1-H), 5.05 (t, 4'-H), 4.66 (dd, 2'-H), 4.46 (dd, 3'-H), 4.20 (m 3-H), 3.95, 3.74 (2 qd, 5-H and 5'-H), 3.36 (t, 4-H), 3.29 (s, OMe), 2.02, 2.00 (2s, 2 OAc), 1.28, 1.20 (2d, 2 Me); for (12): δ 6.50 (d, NH), 5.12 (m, 3'-H), 5.04 (dd, 1'-H), 4.72 (t, 4'-H), 4.72 (d, 1-H), 4.29 (m, 3-H), 3.92, 3.79 (2 qd, 5-H, 5'-H), 3.39 (t, 4-H), 3.34 (s, OMe), 2.17–1.75 (m, CH<sub>2</sub>, CH<sub>2</sub>'), 1.33, 1.17 (2d, 2 Me).

<sup>‡</sup> Characterization data, including microanalyses, mass spectra, and <sup>1</sup>H NMR are in excellent agreement with the proposed structures for the new compounds.

Obtention of the valuable intermediate 2'-iodo-disaccharide (10), ready to be glycosylated, is of great interest since the presence of iodine at C-2' enhances the stabilization of the interglycosidic bond. This avoids the usual problems of transglycosidation generally observed<sup>9,10</sup> during the coupling of the corresponding 2'-deoxy disaccharides. For example, an attempt to glycosylate compound (9) under the same conditions as used with (10) (MeOH, TMSOTf) led to a complex mixture of four compounds which were not analysed in detail.

Although the C-I bond can be removed easily after glycosidation as shown by radical transformation [Bu<sub>3</sub>SnH, azoisobutyronitrile (AIBN), benzene, reflux] of (11) into (12) {syrup, [α]<sub>D</sub><sup>20</sup> -81° (c1, CHCl<sub>3</sub>)}, the 2''-iodo anthracycline derivatives are also worthy of antitumor evaluation if we keep in mind the results reported with other 2'-iodo-monosaccharide glycosides.<sup>11</sup>

Received, 23rd June 1989; Com. 9/02668A

## References

- 1 D. E. Nettleton, Jr., W. T. Bradner, J. A. Bush, A. B. Coon, J. E. Moseley, R. W. Myllymaki, F. A. O'Herron, R. H. Schreiber, and A. L. Vulcano, *J. Antibiot.*, 1977, **30**, 525.
- 2 T. Oki, in 'Anthracycline Antibiotics,' ed. H. S. El Khadem, Academic Press, 1982, p. 75, and references cited therein.
- 3 C. Monneret, A. Martin, and M. Pais, *J. Carbohydr. Chem.*, 1988, **7**, 417.
- 4 C. Ramilarison and C. Monneret, *J. Carbohydr. Chem.*, in the press.
- 5 J.-C. Florent and C. Monneret, *J. Chem. Soc., Chem. Commun.*, 1987, 1171.
- 6 W. Roth and W. Pigman, *Methods Carbohydr. Chem.*, 1963, 405.
- 7 J. Thiem, H. Karl, and J. Schwentner, *Synthesis*, 1978, 696.
- 8 N. Knouzi, M. Vaultier, and R. Carrié, *Bull. Soc. Chim. Fr.*, 1985, 815.
- 9 H. S. El Khadem and A. Liav, *Carbohydr. Res.*, 1979, **74**, 345.
- 10 J. Boivin, C. Monneret, and M. Pais, *Tetrahedron*, 1981, **37**, 4219.
- 11 D. Horton and W. Priebe, *Carbohydr. Res.*, 1985, **136**, 391.